Rhumbline Advisers Candel Therapeutics, Inc. Transaction History
Rhumbline Advisers
- $104 Billion
- Q1 2025
A detailed history of Rhumbline Advisers transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 33,302 shares of CADL stock, worth $220,459. This represents 0.0% of its overall portfolio holdings.
Number of Shares
33,302
Previous 33,302
-0.0%
Holding current value
$220,459
Previous $198,000
5.05%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding CADL
# of Institutions
86Shares Held
15.4MCall Options Held
536KPut Options Held
335K-
Baker Bros. Advisors LP New York, NY2.44MShares$16.1 Million0.16% of portfolio
-
Acorn Capital Advisors, LLC New York, NY2.15MShares$14.2 Million8.46% of portfolio
-
Northpond Ventures, LLC1.94MShares$12.8 Million48.35% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.74MShares$11.5 Million0.0% of portfolio
-
Portolan Capital Management, LLC Boston, MA881KShares$5.83 Million0.41% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $191M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...